Jean Jacques Bienaime

Board Member · BIOMARIN PHARMACEUTICAL INC

Rank #1,977 SEC EDGAR (United States) ↗ Files from United States

Details

Member of the boardPharmaceuticals & BiotechnologyUnited StatesBorn Aug 19, 1953 · age 73ESCP Business SchoolWharton SchoolBMRNSEC CIK 0001221590

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Disclosed holdings
$51.7M
1-day change
▲ 0.06%
Positions on file
4
issuers disclosed in Forms 3/4/5 and Schedules 13D/G

Disclosed holdings over time 53 weekly points

What the 4 currently disclosed positions would have been worth at each week’s closing price. A rising line means the shares got more valuable, not that this person bought more.

How the line is built

Share counts are as last reported to the SEC and held constant; only prices move.

2025-09-05$40.0M – $52.2M2026-09-04

Insider activity Apr 11, 2024 – Mar 11, 2026

Jean Jacques Bienaime is recorded in filings to the U.S. SEC via EDGAR as member of the board, and reported 20 transactions between Apr 11, 2024 and Mar 11, 2026. The buy and sell totals below count only codes P, S.

Why the other codes are excluded

Share awards (A), shares withheld to pay tax (F), option exercises (M) and gifts (G) also appear in the table, but they are consequences of a pay package or a private transfer, not a decision to buy or sell on the open market. Counting them would turn this into a compensation ranking.

Open-market buys (code P)
$355.9K
8 purchases on file priced rows only
Open-market sales (code S)
$6.90M
4 sales on file priced rows only
All reported transactions
20
every code, including awards and exercises
Pattern
Net buyer in the final 12 months of the window
last 12 months of the window

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Jean Jacques Bienaime bought 2,000 Ascendis Pharma A/S (ASND) shares for $492,654 on Aug 14, 2026

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Jean Jacques Bienaime bought 2,000 Ascendis Pharma A/S (ASND) shares for $492,654 on Aug 14, 2026
Date Insider Transaction Shares Price Value Filing
Aug 14, 2026 Jean Jacques Bienaime P Open-market purchase 1,100 held after: 2,000 $245.85 $270,435 SEC filing ↗
Aug 14, 2026 Jean Jacques Bienaime P Open-market purchase 900 held after: 2,900 $246.91 $222,219 SEC filing ↗

Total of the rows above: $492,654, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

3 insiders bought Immunome Inc. (IMNM) shares worth $1,221,179 between Mar 24, 2025 and Mar 26, 2025

Cluster buying

3 different insiders made 4 open-market purchases of this company’s shares within a short window. Each row below is one reported trade.

3 insiders bought Immunome Inc. (IMNM) shares worth $1,221,179 between Mar 24, 2025 and Mar 26, 2025
Date Insider Transaction Shares Price Value Filing
Mar 24, 2025 Jean Jacques Bienaime P Open-market purchase 7,000 held after: 23,615 $8.21 $57,470 SEC filing ↗
Mar 24, 2025 Philip Tsai P Open-market purchase 12,300 held after: 33,300 $8.42 $103,566 SEC filing ↗
Mar 25, 2025 Jean Jacques Bienaime P Open-market purchase 7,800 held after: 31,415 $7.78 $60,684 SEC filing ↗
Mar 26, 2025 Clay B. Siegall P Open-market purchase 137,100 held after: 806,736 $7.29 $999,459 SEC filing ↗

Total of the rows above: $1,221,179, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Reported transactions

Price 0.00 is a real reported figure on gifts (G) and share awards (A) — not a missing number. The 25 most recent rows are grouped into 18 lines by date, company and transaction type — open a line to see every lot with its own source link. We hold 42 on file in total. See the full history on EDGAR ↗

How to read this list

Every row is one line of one Form 4 or Form 5, with the filing it came from. Where the record carries no price at all we leave the cell empty instead of guessing one.

The shares and money on a grouped line add up only the lots listed inside that line, and only when every one of them carries the figure. Where a group mixes more than one reporting currency we leave the money blank rather than convert — no source publishes the rate that conversion would need.

  1. Keros Therapeutics, Inc. KROS P Open-market purchase 1,000 shares $10.3K at $10.27 SEC filing ↗
  2. Ascendis Pharma A/S ASND P Open-market purchase × 2 2,000 shares $492.7K
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    900 $246.91 $222.2K SEC filing ↗
    1,100 $245.85 $270.4K SEC filing ↗
  3. Keros Therapeutics, Inc. KROS P Open-market purchase 1,000 shares $10.6K at $10.61 SEC filing ↗
  4. Keros Therapeutics, Inc. KROS P Open-market purchase 1,000 shares $10.2K at $10.19 SEC filing ↗
  5. INCYTE CORP INCY A Grant or awardnot a buy/sell decisionreported at zero 1,642 shares $0 at $0.00 SEC filing ↗
  6. Immunome Inc. IMNM P Open-market purchase × 3 10,500 shares $204.3K
    The 3 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    1,000 $19.27 $19.3K SEC filing ↗
    3,500 $19.46 $68.1K SEC filing ↗
    6,000 $19.48 $116.9K SEC filing ↗
  7. Immunome Inc. IMNM S Open-market sale × 2 10,500 shares $203.8K
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    10,000 $19.41 $194.1K SEC filing ↗
    500 $19.44 $9.7K SEC filing ↗
  8. Keros Therapeutics, Inc. KROS A Grant or awardnot a buy/sell decisionreported at zero 7,142 shares $0 at $0.00 SEC filing ↗
  9. Ascendis Pharma A/S ASND P Open-market purchase × 3 500 shares $111.6K
    The 3 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    100 $223.50 $22.4K SEC filing ↗
    200 $222.30 $44.5K SEC filing ↗
    200 $223.76 $44.8K SEC filing ↗
  10. INCYTE CORP INCY F Shares withheld for taxesnot a buy/sell decision 13,059 shares $1.27M at $97.10 SEC filing ↗
  11. INCYTE CORP INCY M Option exercise or conversionnot a buy/sell decision 15,000 shares $1.27M at $84.53 SEC filing ↗
  12. Ascendis Pharma A/S ASND P Open-market purchase × 2 400 shares $95.1K
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    200 $239.37 $47.9K SEC filing ↗
    200 $236.24 $47.2K SEC filing ↗
  13. Keros Therapeutics, Inc. KROS P Open-market purchase 1,000 shares $10.6K at $10.58 SEC filing ↗
  14. Immunome Inc. IMNM P Open-market purchase 5,000 shares $103.5K at $20.70 SEC filing ↗
  15. Keros Therapeutics, Inc. KROS P Open-market purchase 1,000 shares $11.7K at $11.70 SEC filing ↗
  16. Immunome Inc. IMNM P Open-market purchase 1,000 shares $21.6K at $21.55 SEC filing ↗
  17. Immunome Inc. IMNM P Open-market purchase 1,000 shares $22.1K at $22.12 SEC filing ↗
  18. Keros Therapeutics, Inc. KROS P Open-market purchase 2,000 shares $22.4K at $11.21 SEC filing ↗

Disclosed holdings

Shares is the amount on the form; value is that amount times the closing price shown. Rows with no closing price are left blank, so they may add up to less than the headline figure.

What is not counted here

Each row is one filing you can open. Private companies, real estate, bonds and crypto are not in SEC insider filings and are therefore not counted here.

Equity positions disclosed to the SEC, with the source filing behind each row.
Issuer Ticker Security Shares Close Value Form Reported Filing
BIOMARIN PHARMACEUTICAL INC BMRN Common Stock 721,325 $66.53 $48.0M 4 EDGAR ↗
INCYTE CORP INCY Common Stock 20,841 $126.75 $2.6M 4 EDGAR ↗
Immunome Inc. IMNM Common Stock 38,415 $26.76 $1.0M 4 EDGAR ↗
Keros Therapeutics, Inc. KROS Common Stock 7,450 $11.32 $84.3K 4 EDGAR ↗

Other insiders at the same companies

People who also file with the SEC at a company where Jean Jacques Bienaime reports shares.

Sharing a filing does not mean they work together day to day — it means both names appear on the same issuer’s insider record.

Sources

The filings linked in the tables above are the sources for every figure on this page.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Profile record last refreshed Sep 8, 2026.